On Monday, Following U.S. Stocks were among the “Top Gainers”: Edwards Lifesciences Corp. (NYSE:EW), Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN), Centene Corp. (NYSE:CNC), United Therapeutics Corporation (NASDAQ:UTHR)
Edwards Lifesciences Corp. (NYSE:EW), with shares inclined 9.82%, closed at $148.64, hitting new 52-week high of $149.71.
Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN), with shares jumped 9.64%, settled at $1.82.
Centene Corp. (NYSE:CNC), with shares climbed 3%, and closed at $67.35, hitting new 52-week high of $67.97.
United Therapeutics Corporation (NASDAQ:UTHR), surged 8.07%, and closed at $176.48, hitting new 52-week high of $176.65.
Latest NEWS regarding these Stocks are depicted underneath:
Edwards Lifesciences Corp. (NYSE:EW)
Edwards Lifesciences Corp. (EW), the global leader in the science of heart valves and hemodynamic monitoring, declared that the final five-year clinical data for high-risk patients treated with the first-generation SAPIEN transcatheter aortic valve in The PARTNER Trial demonstrated equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention. Data from the world’s first prospective randomized trial for transcatheter aortic valve replacement (TAVR) in patients at high risk for surgery were presented as part of the late-breaking clinical trials at the American College of Cardiology’s (ACC) 64th Annual Scientific Session in San Diego, and simultaneously published in The Lancet.
“It’s remarkable that this five-year data report continues to show equivalency between what was then a brand new procedure with a first-generation TAVR device and the gold standard of surgery, which has been honed over 50 years of experience,” said Michael J. Mack, M.D., chair, cardiovascular service line, Baylor Scott & White Health. “Just as we observed in the five-year report from The PARTNER Trial on outcomes in inoperable patients treated with SAPIEN, the high-risk patients also had durable valve performance. These data show that TAVR is an effective treatment for these patients.”
The authors noted no noteworthy differences in all-cause mortality, cardiovascular mortality, stroke or need for repeat hospitalization.
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to assist patients, the corporation partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives.
Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN)
Aoxing Pharmaceutical Corporation, Inc. (AXN), declared that it has reached contracts to sell 1,029,412 shares of its ordinary stock. The sales are being made for the primary purpose of increasing the shareholders equity of the Corporation, and bringing it into compliance with the continued listing requirements of NYSE MKT. The sales will be accomplished after the NYSE MKT approves the listing of the additional shares.
508,000 shares will be sold to officers and employees of Aoxing Pharma at a price of $1.36 per share, which was the market price when the sales contracts were made on March 11, 2015. Comprised of among the purchasers will be Wilfred Chow, CFO (100,000 shares) and Guoan Zhang, VP-Finance (20,000 shares). The proceeds for Aoxing Pharma total $690,880, which will be utilized for working capital purposes. The additional 521,412 shares will be issued to a creditor in satisfaction of $709,120 debt.
Aoxing Pharmaceutical Corporation, Inc. is a US incorporated specialty pharmaceutical corporation with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-administration products.
Centene Corp. (NYSE:CNC)
Formerly on March 5, Centene Corp. (CNC), declared that it will release its 2015 first quarter financial results at about 6:00 AM (Eastern Time) on Tuesday, April 28, 2015, and host a conference call afterwards at about 8:30 AM (Eastern Time) to review the results. Michael F. Neidorff, Chairman and Chief Executive Officer, and William N. Scheffel, Executive Vice President, Chief Financial Officer and Treasurer, of Centene Corporation will host the call.
Centene Corporation operates as a diversified, multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States.
United Therapeutics Corporation (NASDAQ:UTHR)
Formerly on March 10, United Therapeutics Corporation (UTHR), declared that the United States Food and Drug Administration (FDA), as part of the Biologics License Application approval for Unituxin, awarded United Therapeutics a Rare Pediatric Precedingity Review Voucher (PPRV) for neuroblastoma, a rare pediatric disease.
The voucher can be sold (without limitation), and the holder of the voucher can redeem it with a subsequently filed New Drug Application or Biologics License Application, requiring FDA to meet the review aims for a priority review, as opposed to a standard review.
“We are thrilled to be the recipient of this pediatric priority review voucher, and are grateful to the Creating Hope Act for its instrumental role in making this voucher program accessible to encourage development of therapies, like Unituxin, for children with rare conditions and high unmet need,” said Roger Jeffs, Ph.D., United Therapeutics’ President and Co-CEO.
United Therapeutics Corporation, a biotechnology corporation, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
